Guardant Health, Inc. Common Stock (GH) Financial Statements
Historical financial data — 31 statements covering FY2018–FY2025
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tu...
Guardant Health, Inc. Common Stock's revenue increased 32.9% year over year, from $739.0M to $982.0M.
Net income increased 4.6% over the same period, from $-436.4M to $-416.3M.
Over the 7-year period from FY2018 to FY2025, revenue grew by 983% in total.
Operating cash flow grew 23.0% to $-184.8M.
Guardant Health, Inc. Common Stock maintains a negative net profit margin of -42.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $177.2M+5.2% | $-102.6M | $-100.6M | $-100.6M | $-94.0M | $1.61B | N/A | $-1.6M |
| Q3 FY2024 | $191.5M+8.0% | $-107.8M | $-117.3M | $-117.3M | $-51.1M | $1.54B | N/A | $-60.1M |
| Q4 FY2024 | $201.8M+5.4% | $-111.0M | $-126.0M | $-126.0M | $-64.5M | $1.49B | N/A | $-139.6M |
| Q1 FY2025 | $203.5M+0.8% | $-95.2M | $128.7M | $-111.0M | $-62.7M | $1.34B | N/A | $-250.8M |
| Q2 FY2025 | $232.1M+14.1% | $-99.9M | $150.9M | $-106.4M | $-60.3M | $1.33B | N/A | $-305.5M |
| Q3 FY2025 | $265.2M+14.3% | $-92.7M | $171.6M | $-99.0M | $-35.4M | $1.28B | N/A | $-354.5M |
| Q4 FY2025 | $281.3M+6.1% | $-128.5M | $181.8M | $-120.8M | $-26.4M | $2.01B | N/A | $-99.3M |
| Q1 FY2026 | $301.7M+7.3% | $-112.1M | $196.7M | $-121.3M | $-65.6M | $1.92B | N/A | $-181.1M |
Balance Sheet Summary (Latest Period)
Guardant Health, Inc. Common Stock (GH) Financial Statements & Revenue History
Guardant Health, Inc. Common Stock (GH) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry trading at $175.05 with a market capitalization of $23. This page provides 31 historical financial statements for Guardant Health, Inc. Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Guardant Health, Inc. Common Stock reported revenue of $982 million, representing 32.9% year-over-year growth. The net profit margin of -42.4% indicates the company is currently unprofitable..
GH Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Guardant Health, Inc. Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether GH is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track GH's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Guardant Health, Inc. Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of GH's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use GH Financial Data
Investors use Guardant Health, Inc. Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare GH's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how GH's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View GH's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Guardant Health, Inc. Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.GH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.